Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 26;12(23):7325.
doi: 10.3390/jcm12237325.

Antibody-Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?

Pierluigi De Santis  1 , Valeria Sanna  2 , Martina Perrone  1 , Chiara Guarini  1 , Anna Natalizia Santoro  1 , Carmelo Laface  1 , Daniela Carrozzo  1 , Gaia Rachele Oliva  3 , Alessandro Fancellu  4 , Palma Fedele  1
Affiliations
Review

Antibody-Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?

Pierluigi De Santis et al. J Clin Med. .

Abstract

Hormone receptor-positive (HR+) breast cancer (BC) accounts for about 60-70% of all diagnosed BCs, and endocrine therapy has long been the hallmark of systemic treatment for this tumor subtype. However, the therapeutic paradigm of luminal BC has been overcome due to recent evidence of antibody-drug conjugate (ADC) activity (such as trastuzumab deruxtecan and sacituzumab govitecan) in pretreated metastatic HR+ BC patients. Therefore, nowadays, the identification of patients who can benefit more from this approach represents a new challenge, as does the management of new toxicities and the integration of these drugs into the therapeutic algorithm of HR+ metastatic BC patients.

Keywords: ADCs; HER2; HR+ breast cancer; combination therapy; sacituzumab govitecan; target therapy; trastuzumab deruxtecan.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary figure.
Figure 2
Figure 2
(A). Structure of ADCs. (B). Mechanisms of action of ADCs: (1) Identification of target and creation of ADC/antigen complex. (2) Intracellular internalization of ADC/antigen complex. (3) Release of cytotoxic payload. (4) Cell death and involvement of other tumor cells thanks to bystander effect.
See this image and copyright information in PMC

References

    1. Gennari A., André F., Barrios C.H., Cortés J., de Azambuja E., DeMichele A., Dent R., Fenlon D., Gligorov J., Hurvitz S.A., et al. ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients with Metastatic Breast Cancer. Ann. Oncol. 2021;32:1475–1495. doi: 10.1016/j.annonc.2021.09.019. - DOI - PubMed
    1. Luveta J., Parks R.M., Heery D.M., Cheung K.-L., Johnston S.J. Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy. Oncol. Ther. 2020;8:1. doi: 10.1007/s40487-019-00105-0. - DOI - PMC - PubMed
    1. Rakha E.A., El-Sayed M.E., Powe D.G., Green A.R., Habashy H., Grainge M.J., Robertson J.F.R., Blamey R., Gee J., Nicholson R.I., et al. Invasive Lobular Carcinoma of the Breast: Response to Hormonal Therapy and Outcomes. Eur. J. Cancer. 2008;44:73–83. doi: 10.1016/j.ejca.2007.10.009. - DOI - PubMed
    1. O’Connor D.J., Davey M.G., Barkley L.R., Kerin M.J. Differences in Sensitivity to Neoadjuvant Chemotherapy among Invasive Lobular and Ductal Carcinoma of the Breast and Implications on Surgery—A Systematic Review and Meta-Analysis. Breast. 2022;61:1–10. doi: 10.1016/j.breast.2021.11.017. - DOI - PMC - PubMed
    1. Verras G.I., Tchabashvili L., Mulita F., Grypari I.M., Sourouni S., Panagodimou E., Argentou M.I. Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis. Breast Cancer Targets Ther. 2022;14:41. doi: 10.2147/BCTT.S346301. - DOI - PMC - PubMed